Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Rallybio Corporation (RLYB : NSDQ)

• Company Description    Rallybio Corporation is a clinical-stage biotechnology company committed to identifying and accelerating the development of therapies for patients with severe and rare diseases. Rallybio Corporation is headquartered in New Haven, Connecticut. Number of Employees: 25

• Price / Volume Information    Yesterday's Closing Price: $0.40 Daily Weekly Monthly 20 Day Moving Average: 8,009,731 shares Shares Outstanding: 41.61 (millions) Market Capitalization: $16.48 (millions) Beta: -1.17 52 Week High: $1.54 52 Week Low: $0.22 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 19.93% 15.44% 12 Week 58.40% 33.24% Year To Date -58.75% -61.37%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 234 CHURCH STREET SUITE 1020 - NEW HAVEN,CT 06510 USA ph: 203-859-3820 fax: - investors@rallybio.com http://www.rallybio.com

• General Corporate Information    Officers Stephen Uden - Chief Executive Officer; President and Director Martin W. Mackay - Chairman Jonathan I. Lieber - Chief Financial Officer and Treasurer Helen M. Boudreau - Director Wendy K. Chung - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 75120L100 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 41.61 Most Recent Split Date: (:1) Beta: -1.17 Market Capitalization: $16.48 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.83 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.30 Price/Cash Flow: - Price / Sales: 19.43 EPS Growth vs. Year Ago Period: 55.32% vs. Previous Quarter: 16.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: 457.89% ROE 06/30/25 - - 03/31/25 - -72.31 12/31/24 - -76.61 ROA 06/30/25 - - 03/31/25 - -64.78 12/31/24 - -68.19 Current Ratio 06/30/25 - - 03/31/25 - 14.68 12/31/24 - 10.87 Quick Ratio 06/30/25 - - 03/31/25 - 14.68 12/31/24 - 10.87 Operating Margin 06/30/25 - - 03/31/25 - -5,682.19 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - -5,682.19 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - -5,429.72 12/31/24 - -8,732.08 Book Value 06/30/25 - - 03/31/25 - 1.30 12/31/24 - 1.49 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©